Updated on 7 July 2014
South Korean publicly listed bioscience companies in 2013 registered combined revenue of $8.3 billion.
The leading publicly listed bioscience company in South Korea, Yuhan Corporation, clocked $825.6 million in revenue.
Some of the key developments in the country included:
Merck and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, expanded collaboration to develop, manufacture and commercialize MK-1293
Korea and Singapore scientists jointly studied RUNX3, a gene that is intensively studied for its function as a tumour suppressor, and analysed that it is also likely to be a key and critical component of the body's first line of defence against lung cancer development.